Wire · opportunities
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 September 2026 · Fusion42 review
The FDA has granted full approval for the combination of imlunestrant and abemaciclib in treating adult patients with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after progression on endocrine therapy, based on positive phase 3 EMBER-3 trial results showing improved progression-free survival.
This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 18 Sep 2026 and 21 Sep 2026.
◆ ◆ The Wire takeaway
Breast cancer treatment just expanded with a combination drug now fully approved by the FDA, opening a pathway for therapies targeting ESR1 mutations. You need to update your clinical focus and patient outreach to include this new standard of care to stay competitive.
◆ Coverage
10 sources · first reported 18 Sep 2026 · latest 21 Sep 2026
◆ Topics